ClinicalTrials.gg
CompletedNCT00633386Updated Feb 21, 2021

Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery

A Phase 4 interventional study of Celecoxib and Placebo in Arthroscopy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To compare the total analgesic use at 24 hours after arthroscopic knee surgery in patients treated with celecoxib versus placebo.

02

Conditions studied

  • Arthroscopy

Keywords

  • Knee Surgery
  • Arthroscopic Surgery
03

In context

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed knee meniscus pathology requiring ambulatory arthroscopic meniscectomy or partial meniscectomy
  • Willing to participate in study for 36 hours and come to follow-up visit 7 days post-surgery

Exclusion criteria

Exclusion criteria:

  • Osteoarthritis, inflammatory arthritis, or previous fracture of index joint
  • Received acetaminophen or low-dose narcotic within 8 hours of surgery
  • Have received oral (4 weeks), intramuscular (2 months), intra-articular (3 months) or soft-tissue (2 months) injections of of the first dose of study medication or received intra-articular injections of hyaluronic acid in the index joint within 9 months of the first dose of study medication
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    A

    Drug: Celecoxib

  • Placebo comparator
    B

    Other: Placebo

Interventions

  • 400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery

  • OtherPlacebo

    Matched placebo

06

What researchers measure

Primary outcomes

  1. Total analgesic use after surgery

    Time frame: 24 hours

Secondary outcomes

  1. Physical examination

    Time frame: Day 7

  2. Number and percentage of subjects taking analgesic (hydrocodone bitartrate 5 mg/acetaminophen 500 mg [HC/APAP]) after surgery

    Time frame: 1, 2, 6, 8, 10, 12, 24, and 36 hours

  3. Time to analgesic use after surgery

    Time frame: 1, 2, 6, 8, 10, 12, 24, and 36 hours

  4. Cumulative number of HC/APAP tablets taken after first dose of study medication

    Time frame: 1, 2, 6, 8, 10, 12, 36 hours and Day 2

  5. Vital signs

    Time frame: Day 7

  6. Patient's Assessment of Knee Pain, according to visual analogue scale at rest and with movement after surgery

    Time frame: 1, 2, 6, 8, 10, 12, 24 and 36 hours

  7. Change in volumetric measurement of both knees from prior to surgery

    Time frame: Day 7

  8. Patient Treatment Satisfaction Scales after surgery

    Time frame: 24 hours

  9. Adverse events

    Time frame: Day 7

07

Study locations

9 sites
  • Pfizer Investigational Site
    Phoenix, Arizona 85023, United States
  • Pfizer Investigational Site
    Saint Petersburg, Florida 33713, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21218, United States
  • Pfizer Investigational Site
    Springfield, Massachusetts 01199, United States
  • Pfizer Investigational Site
    Springfield, Missouri 65804, United States
  • Pfizer Investigational Site
    Columbia, South Carolina 29204, United States
  • Pfizer Investigational Site
    Johnson City, Tennessee 37601, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Charlottesville, Virginia 22908-0159, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003 and a completion of Aug 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2008
First posted
Mar 12, 2008
Start
Feb 2003
CompletionActual
Aug 2003
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00633386
Responsible party
Sponsor
First posted
Mar 12, 2008
Start date
Feb 2003
Completion
Aug 2003
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion